Navigation Links
JNCI news brief: Melanosome dynamics and sensitivity of melanoma cells to chemotherapy
Date:8/24/2009

Manipulating the functions of melanosomes--the organelles in pigment-producing cells--may enhance the activity of anticancer drugs used against melanoma, according to a new study published online August 24 in the Journal of the National Cancer Institute.

To examine the role of melanosomes in the sensitivity of malignant melanoma to chemotherapeutic agents, Kevin Chen, Ph.D., Vincent Hearing, Ph.D., Michael M. Gottesman, M.D., of the Laboratory of Cell Biology at the National Cancer Institute in Bethesda, Md., and colleagues compared pigmentation and melanosome developmental stage, number, and cellular structures in melanoma cell lines in response to treatment with chemotherapeutic agents.

The authors found that late-stage melanosomes that were damaged and thus could not trap metabolites were toxic to melanoma cells. They also found that melanoma cells that survived cisplatin treatment had more stage II-III functional melanosomesalso known as early melansomes because they have not initiated melanin synthesisthan untreated melanoma cells. In addition, when melanosomes were reverted to relatively early stages, the melanoma cells became more resistant to cisplatin.

"We believe that manipulation of melanosome status either by cytotoxic or by noncytotoxic drugs opens therapeutic avenues and raises the prospect of successfully treating pigment-producing cell-related diseases and, in particular, highly intractable malignant melanomas," the authors write.


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. JNCI news brief: Surgeon training found effective in breast cancer sentinel lymph node trial
2. JNCI news brief: High serum insulin levels and risk of prostate cancer
3. JNCI news brief: Antibody linked to chemotherapy drug inhibits ovarian cancer in lab
4. JNCI news brief: Breast cancer hormone receptor status and risk of a second primary tumor
5. JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
6. JNCI news brief: Improving the biomarker pipeline for early cancer detection
7. In brief: New prognostic indicator for patients with IPF
8. MicroDynamics to Introduce New Microscope at Quality Expo
9. CardioDynamics Shareholders Approve Merger Agreement with SonoSite
10. CardioDynamics Reports Second Fiscal Quarter 2009 Results
11. General Dynamics Awarded $9 Million Contract for U.S. Army Medical Command Lean Six Sigma Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) is pleased ... new executive director. Mr. Still was selected through a careful months-long search by the ... is known to our members, has been a part of building the RBMA since ...
(Date:3/28/2017)... ... 28, 2017 , ... Neurotechnology , a provider of ... attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service and the ... face recognition to enable users to check in and out from anywhere via ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Executives, Staff & ... money to for the Toys for Tots Literacy Campaign at their Semi-Annual Graduation and ... of $70 billion, the U.S. ranks at number 14 internationally in literacy. Statistically, a ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon and ... thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. The ... Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is proud ...
(Date:3/28/2017)... ... 2017 , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader ... women’s hair loss. Although hair transplant procedures can be seen as more of a ... can be two reasons a woman may see her hair thinning. , “We are ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... The National University of Singapore (NUS) ... company, signed a Memorandum of Understanding (MOU) recently ... the region. Under this MOU, ... Technology (BIGHEART) at NUS and Holmusk will establish ... healthcare IT and medical device development. These include ...
(Date:3/27/2017)... , March 27, 2017  A recent study ... only four freestanding hospitals in the country dedicated to ... and reconstructive surgery, concluded that the Surfacide Helios ® ... integral component in reducing bacterial pathogens not killed by ... were published at the American Burn Association,s 49th Annual ...
(Date:3/27/2017)... Germany , March 27, 2017 ... over 7,000 attendees and more than 600 exhibitors ... and discover opportunities and solutions that will advance ... 6 April 2017 at the Messe Stuttgart, ... the preeminent medical technology platform showcasing the key ...
Breaking Medicine Technology: